10月9日，义翘神州跌0.59%，成交额8539.05万元。两融数据显示，当日义翘神州获融资买入额1334.85 万元，融资偿还1241.47万元，融资净买入93.39万元。截至10月9日，义翘神州融资融券余额合计2.87亿 元。 融资方面，义翘神州当日融资买入1334.85万元。当前融资余额2.86亿元，占流通市值的3.19%，融资余 额超过近一年90%分位水平，处于高位。 截至9月10日，义翘神州股东户数2.07万，较上期减少1.44%；人均流通股5787股，较上期增加1.46%。 2025年1月-6月，义翘神州实现营业收入3.24亿元，同比增长6.15%；归母净利润6768.63万元，同比减少 4.59%。 分红方面，义翘神州A股上市后累计派现18.02亿元。近三年，累计派现11.22亿元。 机构持仓方面，截止2025年6月30日，义翘神州十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股71.94万股，相比上期减少8.40万股。 责任编辑：小浪快报 融券方面，义翘神州10月9日融券偿还0.00股，融券卖出600.00股，按当日收盘价计算，卖出金额4.43万 元；融券余量1.22万股，融券余 ...

Group 1 - The company announced a cash dividend distribution plan for the first half of 2025, proposing a payout of 40.00 yuan per 10 shares (including tax) [2] - The record date for the dividend distribution is set for September 19, 2025, while the ex-dividend date is September 22, 2025 [2]

证券代码：301047 证券简称：义翘神州 公告编号：2025-035 北京义翘神州科技股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京义翘神州科技股份有限公司（以下简称"公司"）2025 年半年度权益 分派方案已获 2025 年 9 月 11 日召开的 2025 年第一次临时股东大会审议通过， 现将权益分派事宜公告如下： 一、股东大会审议通过权益分派情况 1、公司于 2025 年 9 月 11 日召开 2025 年第一次临时股东大会，审议通过《关 于 2025 年半年度利润分配预案的议案》，公司 2025 年半年度利润分配方案为： 以公司总股本 121,636,742 股为基数，向全体股东每 10 股派发现金红利 40.00 元 （含税），拟合计派发现金红利总额为 486,546,968.00 元（含税），不送红股， 不以资本公积金转增股本。本次分红后的剩余未分配利润结转以后年度分配。 在权益分派预案披露日至实施权益分派股权登记日期间，若公司总股本发生变 动，将按照分配总额不变的原则相应调整，具体以实际派 ...

Market Overview - The biopharmaceutical sector experienced a slight increase of 0.0% on September 12, with Aopumai leading the gains [1] - The Shanghai Composite Index closed at 3883.69, up by 0.22%, while the Shenzhen Component Index closed at 12996.38, up by 0.13% [1] Top Gainers in Biopharmaceutical Sector - Aopumai (688293) closed at 54.00, with a rise of 4.73% and a trading volume of 20,300 lots, totaling a transaction value of 103 million [1] - Kexing Pharmaceutical (688136) closed at 42.28, increasing by 3.45% with a trading volume of 47,400 lots, amounting to 197 million [1] - Sanofi (688336) closed at 57.07, up by 3.39% with a trading volume of 52,600 lots, totaling 294 million [1] - Tibet Pharmaceutical (600211) closed at 56.60, rising by 3.38% with a trading volume of 93,300 lots, totaling 510 million [1] - Wenqu Pharmaceutical (688488) closed at 16.00, increasing by 2.83% with a trading volume of 86,300 lots, amounting to 134 million [1] Top Decliners in Biopharmaceutical Sector - Rongchang Biopharmaceutical (688331) closed at 107.22, down by 2.68% with a trading volume of 56,400 lots, totaling 611 million [2] - Wanze Shares (000534) closed at 16.02, decreasing by 2.61% with a trading volume of 135,500 lots, amounting to 218 million [2] - Kangtai Biopharmaceutical (300601) closed at 18.63, down by 1.48% with a trading volume of 156,700 lots, totaling 292 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 310 million from institutional investors, while retail investors experienced a net inflow of 132 million [2] - Notable net inflows from retail investors were observed in Kanghua Biological (300841) with 94.86 million, and Xizang Pharmaceutical (600211) with 49.76 million [3] - Conversely, significant net outflows were noted in Rongchang Biopharmaceutical (688331) with 17.13 million and Aopumai (688293) with 18.19 million from retail investors [3]

证券代码：301047 证券简称：义翘神州 公告编号：2025-034 北京义翘神州科技股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过决议的情况。 一、会议召开情况 （一）会议召开时间 （1）现场会议时间：2025 年 9 月 11 日（星期四）14:30。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 9 月 11 日 9:15-9:25、9:30-11:30 和 13:00-15:00；通过深圳证券交 易所互联网投票系统投票的具体时间为：2025 年 9 月 11 日 9:15-15:00 期间的任 意时间。 （二）会议召开方式：本次股东大会采取现场投票与网络投票相结合的方式。 （三）会议召开地点：北京市北京经济技术开发区科创十街 18 号院 11 号楼 215 会议室。 （四）会议召集人：公司董事会。 （五）会议主持人：公司董事长谢良志博士。 （六）本次会议的召集 ...

北京市金杜律师事务所 关于北京义翘神州科技股份有限公司 2025 年第一次临时股东大会的法律意见书 致：北京义翘神州科技股份有限公司 北京市金杜律师事务所（以下简称本所）接受北京义翘神州科技股份有限公 司（以下简称公司）的委托，根据《中华人民共和国证券法》（以下简称《证券 法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管 理委员会（以下简称中国证监会）《上市公司股东会规则》（以下简称《股东会 规则》）等中华人民共和国境内（以下简称中国境内，为本法律意见书之目的， 不包括中国香港特别行政区、中国澳门特别行政区和中国台湾省）现行有效的法 律、行政法规、部门规章、规范性文件和现行有效的《北京义翘神州科技股份有 限公司章程》（以下简称《公司章程》）的规定，指派律师出席了公司于 2025 年 9 月 11 日召开的 2025 年第一次临时股东大会（以下简称本次股东大会）， 并就本次股东大会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2024 年年度股东大会审议通过并于 2025 年 4 月 19 日刊登于深 圳证券交易所网站等中国 ...

Group 1 - The core point of the article is that Yiqiao Shenzhou announced the pledge of shares by its controlling shareholder, Lhasa Ailike Investment Consulting Co., Ltd. [2] - The number of pledged shares is 4,500,000, which represents 6.91% of the shares held by the controlling shareholder and 3.70% of the total share capital of the company [2]

Group 1 - The controlling shareholder of Yiqiao Shenzhou, Lhasa Ailike Investment Consulting Co., Ltd., pledged 4.5 million shares of the company on September 4, 2025, which accounts for 6.91% of its holdings and 3.70% of the company's total share capital [1] - The purpose of the pledged shares is for financing [1] - There are no significant asset restructuring or performance compensation obligations associated with the pledged shares [1]

证券代码：301047 证券简称：义翘神州 公告编号：2025-033 2、股东股份累计质押基本情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： | | | | 本次质押 | 本次质押 | 占其所 | 占公司 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 名称 | 持股数量 （股） | 持股 比例 | 前质押股 | 后质押股 | 持股份 | 总股本 | 已质押股份 限售和冻 | 占已 质押 | 未质押股 份限售和 | 占未质 | | | | | 份数量 （股） | 份数量 （股） | 比例 | 比例 | 结、标记数 | 股份 | 冻结数量 | 押股份 比例 | | | | | | | | | 量（股） | 比例 | （股） | | | 爱力克 | 65,140,056 | 53.55% | 15,000,000 | 19,500,000 | 29.94% | 16.03% | 0 | 0.00% | 0 | 0.00% | | 谢良志 | 2 ...

Group 1: Yiqiao Shenzhou - The company reported a more than 10% year-on-year growth in overseas conventional business revenue in the first half of the year, with the US being the primary market [1] - The performance of reagents was strong, while service revenue slightly declined due to large customer order impacts compared to the same period last year [1] - Future focus will be on enhancing reagent promotion, strengthening the sales team, and leveraging SCB's geographical advantages for business expansion [1] - The company will consider mergers and acquisitions that focus on technology complementarity, strategic regional layout, and upstream and downstream enterprises in the industry chain [1] - The sales volume of culture media business increased, but revenue and profit margins were affected by price competition [1] - The Taizhou subsidiary experienced rapid growth, while the Suzhou subsidiary faced longer expansion cycles due to certification requirements, with overall business showing stable growth [1] Group 2: Huaxiang Co., Ltd. - The company achieved a revenue of 1.98 billion yuan in the first half of the year, representing a year-on-year growth of 2.38%, and a net profit attributable to shareholders of 290 million yuan, up 25.66% year-on-year [2] - The profit growth outpaced revenue growth mainly due to an increase in the proportion of high-margin precision parts revenue to 80.8% and an improvement in gross margin to 23.3%, along with a decrease in expense ratio [2] - Financial expenses decreased primarily due to increased foreign exchange gains, with limited impact from the convertible bond delisting [2] - The company views the decline in white goods production as a temporary fluctuation and plans to offset pressure through increased automotive parts production, cost reduction via "short-process joint casting," and enhancing added value [2] - The company is expanding into the robotics sector, having initiated process validation for metal structural components of reducers, and plans to establish an industrial fund through external acquisitions [2] - Capital expenditure in the second half of the year will focus on "three park construction" to advance the expansion of automotive and industrial equipment industrial parks [2] - The mid-term dividend payout ratio reached 40.11%, with the annual dividend level to be announced later [2]